Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04956692
Title Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Merck Sharp & Dohme Corp.
Indications

lung non-squamous non-small cell carcinoma

lung squamous cell carcinoma

Therapies

Cisplatin + Pembrolizumab + Pemetrexed Disodium

Carboplatin + Pembrolizumab + Pemetrexed Disodium

Carboplatin + Paclitaxel + Pembrolizumab

Carboplatin + Nab-paclitaxel + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST